NOX 19.1% 12.5¢ noxopharm limited

Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-14

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,515 Posts.
    lightbulb Created with Sketch. 337
    "...Drugs That Work In Mice Often Fail When Tried In People

    Most potential new drugs fail when they're tested in people. These failures are not only a major disappointment, they sharply drive up the cost of developing new drugs.
    A major reason for these failures is that most new drugs are first tested out in mice, rats or other animals. Often those animal studies show great promise.
    But mice aren't simply furry little people, so these studies often lead science astray.
    Some scientists are now rethinking animal studies to make them more effective for human health. When scientists first started using animals in research over a century ago, the animals were not regarded as human stand-ins. Scientists studying rats were initially trying to understand rats..."


    https://www.npr.org/sections/health-shots/2017/04/10/522775456/drugs-that-work-in-mice-often-fail-when-tried-in-people
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
12.5¢
Change
0.020(19.1%)
Mkt cap ! $36.52M
Open High Low Value Volume
11.0¢ 12.5¢ 11.0¢ $10.59K 85.43K

Buyers (Bids)

No. Vol. Price($)
2 473711 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
12.5¢ 99999 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.